title: Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome.
authors: Philip J
authors: PJ
authors: Kahn
authors: Randy Q
authors: RQ
authors: Cron
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D057915:Drug Substitution; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D055501:Macrophage Activation Syndrome / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D053590:Interleukin 1 Receptor Antagonist Protein